PharmAbcine Inc.

🚨 Exciting Update from PharmAbcine! 🚨 PharmAbcine has received unanimous safety approval from the Safety Review Committee (SRC) for the 4mg single-dose cohort in its Phase 1 clinical trial of PMC-403 for treating neovascular age-related macular degeneration (nAMD)! 🙌 This innovative TIE2-activating antibody PMC-403 is With the aging population on the rise, this could be a game-changer for AMD treatment. Stay tuned for more updates! 👁️🗨️ For more information, please see the link below Press Release Link: https://bit.ly/4h9Lwt6 #PharmAbcine #AMD #Biotech #ClinicalTrials #Innovation #PMC_403 #TIE2 #Age_related_Macular_Degeneration #First_in_Class #Ophthalmology

We are thrilled to share an update on the progress of our PMC-309 program, a VISTA-targeting immuno-oncology drug. PMC-309 has successfully received safety approval for the first dose cohort (0.2mg/kg) in our Phase 1a/b clinical trial for patients with advanced or metastatic solid tumors in Australia. The second dose cohort (0.5mg/kg) is currently underway. Our commitment to developing next-generation immuno-oncology drugs continues as we advance PMC-309 through higher dose cohorts. For more information, please see the link below: Press Release Link: https://bit.ly/4cAGweC #PharmAbcine #ImmunoOncology #ClinicalTrials #InnovativeTherapies #PMC_309 #VISTA

안녕하십니까?  파멥신 IR/PR팀 입니다. VISTA 표적 면역 항암제 'PMC-309'의 호주 임상 1a/b상 진행 현황을 알려드립니다! 이번 임상시험은 총 67명 진행성 또는 전이성 고형암 환자를 대상으로 진행 중이며, 현재 최저 용량군에서 다음 용량군인 (0.5mg/kg)으로 현재 투여 중에 있습니다, 최저 용량군은 시작에 불과하며, 점층적으로 안전성을 입증 할 수 있도록 최선을 다 하도록 하겠습니다. 파멥신 IR/PR 팀 드림 자세한 내용은 아래 링크로 통해 확인 가능합니다. 홈페이지 : https://bit.ly/4f8Q0PZ

PharmAbcine is very delighted to announce that the Phase 1 safety data from intravitreal 3mg single-dose of PMC-403 in patients with neovascular age-related macular degeneration has been approved by the Safety Review Committee. The clinical study will progress to the fourth single-dose group of 4mg and first multiple-dose group of 3mg in parallel. Macular degeneration is a leading cause of blindness caused by aging-related damage to the retina. PMC-403 is a novel TIE2-activating antibody with the mechanism of stabilizing pathological and leaky blood vessels. Once Phase 1 clinical study is completed successfully with promising data, PMC-403 can potentially be a new treatment option for macular degeneration patients worldwide. For more information please see the link below: Press Release Link: https://bit.ly/4csyrIP #PharmAbcine #PMC_403 #TIE2 #MacularDegeneration #ClinicalStudy

파멥신 美 자회사 윈캘바이오, 새로운 시장 개척에 청신호! 🎉 ARVO 2024에서 주사 대체 점안제 전임상 결과발표 윈캘바이오는 OPC 스크리닝 플랫폼을 통해 안구 깊숙한 부위까지 치료제를 전달할 수 있음을 동물 실험으로 입증했으며, 주사제와 유사한 효과를 확인했습니다. 🎈자세한 내용은 아래 링크로 통해 확인 가능합니다. 윈캘바이오 홈페이지 : www.wincalbio.com 파멥신 홈페이지 : https://bit.ly/3QSGpCf #파멥신 #윈캘바이오 #ARVO2024 #점안제 #황반변성치료제 #OPC스크리닝플랫폼 #Ophthalmology #Biotech #EyeDrop #OPC #wetAMD #DR #DME #VisionLoss #WincalBio #PharmAbcine

🚀Exciting news! PharmAbcine's U.S. subsidiary WincalBio presented promising data on their eye drop formulations at #ARVO2024. 🚩 For further information, we invite you to explore the details through the following link: https://bit.ly/3VegrM9 #Ophthalmology #Biotech #EyeDrop #OPC #wetAMD #DR #DME #VisionLoss #WincalBio #PharmAbcine

[Wincal BioPharm] Going to #ARVO2024? Don’t miss our oral presentation featuring preclinical data on our game changing eye drop OPC platform. More details on the presentation here: https://bit.ly/4b8px1Q #WincalBio #EyeDrop #OPC #wetAMD #DR #DME #VisionLoss

🚀 Exciting News! 🌐 PharmAbcine has registered a patent for PMC-403 in Japan, marking the third patent after Russia and Singapore. PMC-403's novel mechanism normalizes vessel leakage, offering hope for neovascular age-related macular degeneration and more. Currently in Phase 1 trials in Korea. 🌟 For further information, we invite you to explore the details through the following link: 📌 https://bit.ly/3Ih8dLL #PharmAbcine #PMC_403 #Age_relatedMacularDegeneration #ClinicalStudy #InnovationInHealthcare

파멥신의 혈관정상화 신약후보물질인 PMC-403이 최근 일본 특허 등록결정!🎉 이후 미국과 유럽 등 다음 특허 등록 소식을 전해드리도록 최선을 다하겠습니다 :-) 📌자세한 뉴스는 아래 링크로 더보기 https://bit.ly/49kTQ53 #혈관안정화 #특허 #일본 #PMC_403 #황반변성 #임상1상

파멥신 美 자회사 '윈캘바이오' 2024 ARVO에서 주사대체 점안제 전임상 결과를 첫공개합니다! 세계 최대규모인 미국안과학회(ARVO)에서 발표하게 된 Venice Chiueh 박사는 기존 환자들의 안구 주사방식(IVT)이 점안제 방식으로 바뀔 수 있도록 임상연구의 성공을 위해 최선을 다할 것이라고 합니다! 자세한 내용은 아래 링크로 통해 확인 가능합니다. 🌍 윈캘바이오 홈페이지 : www.wincalbio.com 🌎 파멥신 홈페이지 : https://bit.ly/3P4xj4z